Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective

Hijová, Emília; Bertková, Izabela; Benetinová, Veronika

doi:10.3390/biomedicines14061267

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Open AccessReview

Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective

by

Emília Hijová

^*

,

Izabela Bertková

and

Veronika Benetinová

Center of Clinical and Preclinical Research, MediPark, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SNP 1, 040 11 Košice, Slovakia

^*

Author to whom correspondence should be addressed.

Biomedicines 2026, 14(6), 1267; https://doi.org/10.3390/biomedicines14061267

Submission received: 13 April 2026 / Revised: 28 May 2026 / Accepted: 29 May 2026 / Published: 1 June 2026

(This article belongs to the Special Issue Cardiometabolic Diseases: Molecular Biomarkers and Treatment Strategies)

Download Versions Notes

Abstract

The gut microbiome plays a key role in the pathogenesis of cardiovascular disease through systemic inflammation, impaired lipid metabolism, and proatherogenic gut metabolites like trimethylamine N-oxide. Gut dysbiosis contributes to decreased level of microbial metabolites such as short-chain fatty acids, bile acids, coprostanol, and phenylacetylglutamine, as well as increased intestinal permeability and platelet hyper-reactivity, and exacerbating cardiovascular risk. New microbiome-focused treatments such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation are showing potential to help reduce cardiovascular diseases. However, bringing these therapies into clinical settings is difficult because they vary by strain and individual response. The gut–heart connection offers an innovative approach to preventing and treating heart condition, but additional research is needed to ensure lasting effectiveness and safety.

Keywords: gut microbiota; cardiovascular diseases; microbial metabolites

Share and Cite

MDPI and ACS Style

Hijová, E.; Bertková, I.; Benetinová, V. Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective. Biomedicines 2026, 14, 1267. https://doi.org/10.3390/biomedicines14061267

AMA Style

Hijová E, Bertková I, Benetinová V. Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective. Biomedicines. 2026; 14(6):1267. https://doi.org/10.3390/biomedicines14061267

Chicago/Turabian Style

Hijová, Emília, Izabela Bertková, and Veronika Benetinová. 2026. "Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective" Biomedicines 14, no. 6: 1267. https://doi.org/10.3390/biomedicines14061267

APA Style

Hijová, E., Bertková, I., & Benetinová, V. (2026). Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective. Biomedicines, 14(6), 1267. https://doi.org/10.3390/biomedicines14061267

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI